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The objective of this multicenter prospective study was to determine
the clinical efficacy and toxicity of a polychemotherapeutic third
generation regimen, VACOP-B, with or without radiotherapy as front-
line therapy in aggressive localized non-Hodgkin’s lymphoma. Ninety-
three adult patients (47 males and 46 females, median age 45 years)
with aggressive localized non-Hodgkin’s lymphoma, 43 in stage I and
50 in stage II (non-bulky), were included in the study. Stage I patients
received VACOP-B for 6 weeks plus involved field radiotherapy and
stage II patients received 12 weeks VACOP-B plus involved field
radiotherapy on residual masses. Eighty-six (92.5%) achieved com-
plete remission and 4 (4.3%) partial remission. Three patients (3.2%)
were primarily resistant. Ten-year probability of survival, progres-
sion-free survival and disease-free survival were 87.3, 79.9 and 83.9%,
respectively. Eighty-four patients are surviving at a median observa-
tion time of 57 months (range: 6-126). Statistical analysis showed no
difference between stages I and II in terms of response, ten-year
probability of survival, progression-free survival or disease-free sur-
vival. Side effects and toxicity were negligible and were similar in the
two patient groups. The results of this prospective study suggest that 6
weeks of VACOP-B treatment plus radiotherapy may be the therapy of
choice in stage I aggressive non-Hodgkin’s lymphoma. Twelve weeks of
VACOP-B treatment with or without radiotherapy was shown to be
effective and feasible for stage II. These observations need to be
confirmed by a phase III study comparing first and third generation
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Introduction
In the 1960’s and 70’s radiotherapy was
widely used for the treatment of localized
non-Hodgkin’s lymphoma (NHL) but results
were unsatisfactory due to the high inci-
dence of relapse and progression (1-5). Pa-
tients with localized, aggressive, non-bulky
stage I and II NHL can be cured using first
generation regimens containing doxorubi-
cin, alone or in combination with involved
field radiotherapy (6-8). In 1998, Miller et
al. (7) published a randomized study com-
paring 3 cycles of classical first generation
polychemotherapy containing doxorubicin
(CHOP) plus involved field radiotherapy with
6-8 cycles of CHOP treatment for localized
intermediate and high-grade NHL, without
considering stage during randomization. The
study cited suggested the advantage of com-
bined therapy (CHOP plus radiotherapy) in
terms of overall and progression-free sur-
vival. Further advantages included a decrease
in both life-threatening toxic effects and heart
failure due to cumulative doxorubicin toxic-
ity (7,8). The CHOP regimen seems to repre-
sent a good treatment for early stage aggres-
sive NHL. However, 6-8 cycles of CHOP
treatment resulted in an increase in extra-
hematological toxicity (7) without the po-
tential advantages of disease eradication or
avoiding the complications of radiotherapy
(5,7,8). Left ventricular function can be sig-
nificantly reduced in patients treated with 8
cycles of CHOP (7). Phase II studies seem to
confirm the encouraging results obtained by
combining chemotherapy and radiotherapy
(9). Three cycles of doxorubicin-based che-
motherapy and involved field radiotherapy
seem to be a successful approach with re-
spect to long-term outcome for most patients
with early stage aggressive NHL (10). When
compared to standard CHOP therapy, inten-
sive second and third generation regimens
seem to offer no advantage when used as
front-line therapy in advanced diffuse and
aggressive NHL (6,11,12). However, there
are few reports of second or third generation
regimens alone or combined with radio-
therapy as front-line treatment for localized
NHL (13,14).
VACOP-B is a third generation regimen
consisting of etoposide, doxorubicin, cyclo-
phosphamide, vincristine, prednisone, and
bleomycin which was effective as front-line
therapy for advanced and diffuse NHL
(15,16). When compared with the CHOP
protocol, toxicity was very low and treat-
ment time was shorter in this subset of pa-
tients.
Thus, in October 1991, the Italian Non-
Hodgkin’s Lymphoma Co-operative Study
Group (NHLCSG) began a controlled, pro-
spective, non-randomized multicenter study
to analyze the role of VACOP-B with or
without radiotherapy in improving outcome
and reducing chemotherapy-related toxicity
in patients with aggressive localized NHL.
Design and Methods
Eligibility criteria and treatment
This was a prospective, non-randomized
study, involving 8 NHLCSG centers, Italy.
The study began in October 1991 and ended
in December 2001. Study eligibility criteria
were as follows: patient age from 16 to 60
years, patients with diffuse intermediate or
high-grade malignancy NHL according to
the Working Formulation Classification (17)
(excluding lymphoblastic lymphoma and
Burkitt’s lymphoma); Ann Arbor System
(18) stage I (including bulky disease), stag-
ing I-E non-bulky, stage II or non-bulky
stage II-E disease; normal renal, pulmonary,
cardiac, and hepatic function. Performance
status (PS) was established according to the
Eastern Cooperative Oncology Group sys-
tem (19). Bulky disease was defined as a
mediastinal mass >0.33 of the maximum
intrathoracic diameter as determined by a
chest X-ray or any other mass with a maxi-
mal diameter ≥10 cm. Previously treated
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patients or those with a positive serology for
human immunodeficiency virus and hepati-
tis B or C virus were excluded. All patients
were ambulatory. Patients with a history of
congestive heart disease, another cancer, or
symptoms or findings compatible with cen-
tral nervous system involvement by lym-
phoma were excluded. All participants gave
written informed consent before treatment.
The study protocol was approved by the
institutional review board of each participat-
ing hospital. All cases were reviewed by a
central committee to confirm the diagnosis.
After pretreatment evaluation, 93 patients
were assigned to receive 6 cycles of VACOP-
B followed by involved field radiotherapy
(stage I, 43 patients) or 12  cycles of VACOP-
B (stage II, 50 patients). Patients in stage II
who still presented a residual mass were
treated with involved field radiotherapy. The
radiotherapy doses ranged from 4000 to 5000
cGy administered in 20 fractions over a pe-
riod of 4 weeks. Most patients received 4,500
cGy. VACOP-B was given according to the
original protocol (15). VACOP-B is a 12-
week third generation protocol consisting of
doxorubicin, 50 mg/m2 iv, in the 1st, 3rd,
5th, 7th, 9th, and 11th weeks of treatment;
cyclophosphamide, 350 mg/m2 iv, in the 1st,
5th and 9th weeks; VP-16, 50 mg/m2 iv, on
day 1 and 100 mg/m2 po on days 2-3 in the
3rd, 7th, and 11th weeks; bleomycin, 10 U/
m2 iv, and vincristine, 1.2 mg/m2 iv, in the
2nd, 4th, 6th, 8th, 10th, and 12th weeks, and
prednisone, 45 mg/m2 per day po, in the 1st
week and on alternate days until the end of
treatment. Stage II patients who achieved
complete remission after 12 cycles of
VACOP-B were followed until the end of
the study.
Disease status was defined on comple-
tion of treatment (chemotherapy alone or
combined chemoradiotherapy). Patients in
partial remission, non-responders, or relapsed
patients received a second line conventional
chemotherapy: 6 cycles of “CEMP” proto-
col repeated at 21-day intervals (cyclophos-
phamide, 650 mg/m2 on day 1; VP-16, 150
mg/m2 on day 1; mitoxanthrone, 12 mg/m2
on day 1; methylprednisone, 60 mg daily
given orally on day 1 to 5) (20) or 6 cycles of
the traditional CHOP protocol (6). Patients
who had not obtained complete remission
after two conventional chemotherapy series
underwent an intensified phase including
cyclophosphamide at the dosage of 7 g/m2 to
reduce tumor burden and to collect peripher-
al blood progenitor cells for subsequent au-
tologous stem cell transplant (21).
Staging and response criteria
Staging included routine blood chemis-
try tests, complete blood cell counts and
differentials, ECG, and chest X-ray. Extent
of disease was confirmed by physical exami-
nation, bilateral iliac crest bone marrow bi-
opsies, and computed tomography (CT) of
the chest, abdomen, and pelvis. Magnetic
resonance imaging (MRI) and radionuclide
scans were performed when required. Lapa-
rotomy and/or laparoscopy to confirm clini-
cal and instrumental stage were not per-
formed.
Complete re-staging was performed at
the end of treatment. This included two pos-
terior iliac crest biopsies, CT of chest, abdo-
men, and pelvis, MRI scan and radionuclide
scan when required. Re-staging was per-
formed every three months during the first
year after completion of therapy, every 6
months in the second year, and annually
thereafter. In addition, patients were care-
fully followed and all necessary tests were
performed when clinically required.
Complete remission was defined as the
complete disappearance of the disease and
normalization of all laboratory values for at
least 4 weeks. Patients with persistent CT
abnormalities but >75% regression of the
initial tumor were defined as being in uncon-
firmed complete remission if in complete
remission in all other parameters (22). Par-
tial remission was defined as a >50% to 75%
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reduction of all measurable lesions. Non-
response was defined as a less than 50%
reduction in tumor mass, and progressive
disease as an increase of at least 25% in the
size of disease or the appearance of new
lesions.
Patients who received consolidation ra-
diotherapy were assessed for response on
completion of therapy. The toxicity of con-
ventional chemotherapy was evaluated ac-
cording to World Health Organization
(WHO) criteria.
Statistical analysis
This was an open-label phase II study.
The primary end-point was tumor response.
Overall survival, progression-free survival
(progression-free survival) and disease-free
survival (disease-free survival) were assessed
as secondary end-points.
It is assumed that the combination thera-
py will be of no further interest for patients
with stage I-II NHL if the true tumor re-
sponse rate is less than 60% (H0). The alter-
nate hypothesis (H1) assumes that a true
response rate of 75% or more would be of
considerable interest in patients with the
disease. The study took place in two stages:
the first stage included 34 patients. If less
than 21 responses had been seen, the trials
would have been terminated. Otherwise, ac-
crual was to continue up to a total of 95
patients with a 5% alpha-error and a power
of 90%. If more than 64 responses were
observed we would conclude that the combi-
nation therapy was promising for further
study.
Patients were enrolled by telephone from
the Central Office (University of Genoa,
Istituto dei Tumori, Italy). Analysis was based
on disease status on December 15th, 2002.
Overall survival was measured from the date
of enrollment to the date of death or last
follow-up evaluation. Progression-free sur-
vival was applied to all patients and was
calculated from the date of enrollment to the
date of relapse, progression, death or last
follow-up evaluation. Disease-free survival
was only applied to patients who achieved
complete remission. Duration was calculated
from the date of complete remission assess-
ment to the date of relapse or last confirma-
tion of complete remission status. Actuarial
curves were estimated according to the
Kaplan and Meier (23) method. The statisti-
cal significance of the difference between
groups was determined by the log-rank test.
The relationship between parameters and
outcome was examined by univariate and
multivariate analysis according to Cox’s haz-
ards regression model (24). Survival analy-
sis according to a number of prognostic fac-
tors included in the step-wise Cox analysis
was as follows: PS (0 vs 1), stage (I vs II), and
lactate dehydrogenase (LDH) (normal vs
abnormal). We also carried out a retrospec-
tive analysis of patients according to the
International Non-Hodgkin’s Lymphoma
Prognostic Factors Project (International
Prognostic Index, IPI) (25) stage modified
by Miller et al. (7) and adjusted for age ≤60
years. The adverse factors considered were
stage II, increase of LDH level, and a PS > 1.
Age over 60 years was removed from the
analysis according to the original IPI indica-
tion. Statistical tests for comparison of main
objectives were regarded as significant if the
two-sided P value was less than 0.05. The χ2
test or the Fisher exact test was used to
compare toxicity according to group.
Results
Patient characteristics
Ninety-three patients with a median age
of 45 years (range 17-60) entered the study.
Forty-seven patients were males and 46 were
females; 43 were in stage I and 50 were in
stage II; 79 patients had a PS = 0 and 14
patients a PS = 1. Seven patients in stage I
and 15 patients in stage II showed mediasti-
nal involvement. Two stage I patients had
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mediastinal bulky disease. Extranodal in-
volvement was present in 8 stage I-E patients
(sinus, 4; breast, 2; bladder, 1; bone, 1) and
in 5 stage II-E patients (sinus, 4; thyroid, 1).
All patients received VACOP-B with or with-
out radiotherapy according to the protocol.
There were no patients with a PS > 1. The
distribution of patients according to the IPI
stage, modified by Miller et al. (7) and ad-
justed for age ≤60 years, only included pa-
tients with no more than 2 negative prognos-
tic factors. Histology features and other pa-
tient characteristics at diagnosis are reported
in Table 1.
Response to treatment and survival
All patients were available for response.
At the end of therapy, 86 of 93 patients
(92.4%) were in complete remission or in
unconfirmed complete remission (3 patients),
4 in partial remission (4.3%) and 3 (3.2%)
were non-responders.
After 6 cycles of VACOP-B, 37 stage I
patients entered complete remission + un-
confirmed complete remission (1 patient)
(86%), 2 achieved partial remission and 4
were non-responders. After involved field
radiotherapy, 41 stage I patients were in
complete remission (95%) and 2 were non-
responders (5%). These last 2 patients died 7
and 16 months after diagnosis because of
progression in spite of a polychemoterapeutic
salvage regimen containing cisplatinum and
Citarabin (DHAP) (26) in one case and high-
dose therapy in the other. Eleven stage I
patients (26%) had received treatment fol-
lowing a diagnostic biopsy without visible
tumor masses. Four patients refused to un-
dergo involved field radiotherapy.
After 12 courses of VACOP-B, 40 stage
II patients achieved complete remission +
unconfirmed complete remission (2 patients)
(80%), 8 entered partial remission and 2
patients were non-responders. Ten patients
received involved field radiotherapy. At the
end of treatment 45 patients were in com-
plete remission (90%), 4 in partial remission
and 1 patient was a non-responder. Four
patients of this last group showed a stable
persistence of minimal residual masses (≤1.5
cm) after radiotherapy, and required exten-
sive re-staging including an MRI scan and
radionuclide scan. They were judged to be in
complete remission three months after ra-
diotherapy. Salvage therapy in the 4 partial
remission patients and in 1 non-responder













Diffuse mixed 13/93 14.0
Diffuse large-cell 56/93 60.2























NA = not available. *Adverse risk factors were
defined as a stage II, increased lactate dehydro-
genase, and a performance status of 2 (IPI stage
modified by Miller et al. (7) and adjusted for age).
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3 and 6 months after complete remission.
After conventional therapy both achieved a
second complete remission. Eight of 45 (18%)
stage II patients relapsed within a median
time of 14 months (range: 6-43 months) after
complete remission, 4 at a different site and
4 at the initial site of disease (3 of these had
previously received involved field radio-
therapy). These patients received DHAP (4
patients), CHOP plus radiotherapy (1 pa-
tient), and DHAP plus high-dose therapy (3
patients). Four patients achieved a second
complete remission, while 4 died from pro-
gressive disease within a median time of 9
months after relapse.
On July 7, 2003, 84 of 93 patients were
still alive. The median follow-up observa-
tion time for these patients was 57 months
(range: 6-126 months). The ten-year sur-
vival estimate for patients was 87.3% (SEM
4.2%). The ten-year probability of disease-
free survival and of progression-free sur-
vival was 83.9% (SEM 4.6%) and 79.9%
(SEM 4.6%), respectively (Figure 1).
The overall survival rates at 8 years were
94.5% (SEM 3.8%) for stage I patients and
82.8% (SEM 6.1%) for stage II patients (P =
0.2; Figure 2). The probability of disease-
free survival and of progression-free sur-
vival was similar in both groups of patients
with a trend in favor of stage I patients
(Figure 2). Univariate analysis for PS and
disease-free survival did not show any dif-
ference in relation to prognostic factors.
Univariate analysis for progression-free sur-
vival showed PS as an adverse factor pre-
dicting a poor outcome (P = 0.02).
The ten-year estimates of overall sur-
vival according to the IPI stage, modified by
Miller et al. and adjusted for age ≤60 years,
were 96.1% (SEM 3.8%) for patients with
zero risk factors (36 patients), 85.3% (SEM
5.8%) for patients with 1 risk factor (49
patients), and 57.1% (SEM 24.9%) for pa-
tients with 2 risk factors (8 patients) (P =
0.07). Pairwise comparison showed a sig-
nificant difference between patients without
Figure 1. Overall survival (con-
tinuous black line), disease-free
survival (dotted line) and pro-
gression-free survival (broken
line) for 93 non-Hodgkin’s lym-
phoma patients treated with
VACOP-B with or without radio-
therapy.
patient consisted of the DHAP regimen for 2
patients and high-dose therapy for 3 pa-
tients. Two patients in partial remission
achieved complete remission after DHAP
and 3 died because of progressive disease 7,
9 and 9 months after diagnosis, respectively.



































































Figure 2. Overall survival (A), dis-
ease-free survival (B) and pro-
gression-free survival (C) for
non-Hodgkin’s lymphoma pa-
tients in stages I and II treated
with VACOP-B with or without
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negative factors and patients with 2 negative
factors (P = 0.01).
Toxicity
The toxicity was similar in the two pa-
tient groups (Table 2), the first (stage I)
treated with 6 courses of VACOP-B plus
involved field radiotherapy and the second
(stage II) treated with 12 courses of VACOP-
B with or without involved field radiotherapy.
Table 2 summarizes grade 3-4 toxicity of the
two treatments. We observed a trend at the
limit of statistical significance in terms of
anemia and mucositis in favor of patients
receiving less chemotherapy. Six patients
(6.5%) experienced brief episodes of fever
of unknown origin during granulocytopenia,
and 3 patients (3.2%) suffered short-lived
grade 1-2 bronchitis. Cardiac grade 1 toxic-
ity was observed in two of 93 patients (2.2%).
Nine patients required a delay in drug ad-
ministration (median: 7 days). Growth fac-
tors were not used.
No treatment-related mortality was ob-
served. No patients developed a secondary
tumor.
Discussion
The aim of the present study was to de-
fine the efficacy and toxicity of a third gen-
eration regimen, VACOP-B, as front-line
therapy for aggressive and localized NHL.
With this study we were able to demonstrate
that VACOP-B offers a high percentage of
stable complete remissions with a low re-
lapse rate and low toxicity. On completion of
therapy, the complete remission rates in stage
I and II were 95 and 90%, respectively.
These results compare favorably to those
obtained by Miller et al. (7) who reported a
complete remission rate of 82% in patients
receiving 3 cycles of CHOP plus radiotherapy
and a complete remission rate of 80% in
patients treated with 6-8 cycles of CHOP
chemotherapy alone.
Current practice is to treat this category
of patients with CHOP chemotherapy or other
regimens containing doxorubicin. Combin-
ing or alternating chemotherapy and radio-
therapy presents significantly superior re-
sults to those obtained with radiotherapy
alone (2-5,7-10) and represents the most
common treatment method for these patients.
Radiotherapy alone yielded 5-year survival
rates ranging from 56 to 100% for patients
with stage I disease and from 0 to 55% for
patients in stage II (1-5). Studies using che-
motherapy with and without radiotherapy
reported 5-year survival rates ranging from
about 70% to about 80%, with no statisti-
cally significant difference between stage I
and stage II disease (7-10). Our results show
a 6-year survival probability of 94.5% for
stage I patients and 82.8% for stage II (P =
0.2). These results correlate well with previ-
ously published data reporting a similar com-
plete remission, survival and disease-free
survival probability using third generation
regimens (13,14), with very low treatment-
related toxicity.
The problem with using radiotherapy
alone seems to be represented by the high
relapse rate after treatment. As previously
reported in a randomized study (5), this is
more than 50%. The problem with using
conventional chemotherapy alone seems to
be represented by the hematological and ex-
Table 2. Toxicity in 93 patients according to disease stage.
Grade (WHO) Stage I Stage II
3 4 3 4
Anemia 3
Granulocytopenia 4 1 3 1
Fever of unknown origin 1
Peripheral neurotoxicity 1




Stage I = 43 patients; stage II = 50 patients. Non-Hodgkin’s lymphoma was staged as
described elsewhere (18).
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tra-hematological toxicity (7). We could use
50% of conventional chemotherapy courses
followed by involved field  radiotherapy, as
suggested by others (7-10), to achieve the
best results while avoiding treatment-related
toxicity. Adjuvant radiotherapy should be a
necessary component of the treatment pro-
gram when localized residual disease still
remains at the end of chemotherapy. Miller
et al. (7) showed in a randomized study that
radiotherapy is useful not only in reducing
the number of CHOP cycles with a conse-
quent reduction in cardiac doxorubicin-re-
lated toxicity, but also in improving overall
outcome.
Our study design was partially consistent
with these considerations. Stage I patients
received 6 cycles of VACOP-B plus adju-
vant involved field radiotherapy at the site of
initial disease. Stage II patients received
VACOP-B for 12 cycles plus involved field
radiotherapy at the site of residual disease.
Adjuvant radiotherapy improved the com-
plete remission rate in about 10% of both
groups of patients. Grades 3 and 4 granulo-
cytopenia occurred in about 10% of patients
but infections were negligible and short-
lived, and growth factors were not required.
Extra-hematological toxicity was very low,
apart from alopecia which was seen in the
majority of patients. No patients died be-
cause of treatment. Two patients presented
grade 1 cardiac toxicity. Miller et al. (7)
reported life-threatening toxicity in 40% of
patients treated with 8 cycles of CHOP and
in 30% of patients treated with 3 cycles of
CHOP plus radiotherapy. The same authors
reported a “disconcerting” finding of myo-
cardial toxicity associated with 8 cycles of
CHOP chemotherapy. Shenkier et al. (10)
treated patients with 3 cycles of CHOP or
CHOP-like regimens plus involved field ra-
diotherapy and reported a complete remis-
sion rate of 97%. After treatment, 2 patients
died of sepsis, 1 patient of myocardial in-
farction, and about 20% of new malignan-
cies were observed at a median time of 51
months after the diagnosis of aggressive lym-
phoma. In the present series, no patient de-
veloped a secondary tumor. The reasons for
these differences in terms of toxicity and
secondary tumors are probably due to the
low age of our patients (younger than 60
years). If we compare this with the two stud-
ies discussed above we see that the first
study included about 50% of patients older
than 60 years while in the second study
patients had a median age of 64 years. The
comparison of toxic effects between 6 and
12 weeks of VACOP-B with or without ra-
diotherapy according to the trial design
showed no statistical difference apart from
mucositis which was more evident in pa-
tients receiving 12 weeks of VACOP-B.
However, according to our observation, 12
weeks of VACOP-B followed by involved
field  radiotherapy seem to represent a good
choice of treatment for stage II patients in
terms of efficacy and low toxicity.
In our series, univariate analysis showed
a poor outcome in patients with a PS = 1
(WHO). We were not able to stratify our
patients into 4 groups according to the IPI
stage modified by Miller et al. (7) and ad-
justed for age ≤60 years because no patient
showed a PS > 1. However, patients with 2
negative factors showed a poorer outcome
in terms of survival than those with no nega-
tive factors at diagnosis. In recent years
new treatment strategies have been employed
ranging from anti-CD20 (rituximab) to
anthracycline chemotherapy regimens,
particularly in elderly patients (27,28) in
order to improve survival in large cell lym-
phomas.
In conclusion, the third generation
VACOP-B regimen with or without radio-
therapy in patients younger than 60 years of
age presenting localized disease was shown
to be effective and feasible, and was charac-
terized by very low toxicity. However, a
randomized trial comparing a first genera-
tion regimen (CHOP or similar) with or with-
out radiotherapy and a third generation regi-
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men (VACOP-B) with or without radio-
therapy is required to confirm our observa-
tions. It would also be useful to study a
reduced chemotherapy regimen (6-week
VACOP-B) plus radiotherapy in patients with
stage II to evaluate the possibility of an even
shorter duration of treatment, thereby reduc-
ing toxicity without compromising efficacy.
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